{
    "nct_id": "NCT06601218",
    "official_title": "A Phase I Study of the Effects of Cannabis on Cancer Burden: Placebo-Controlled, Double-Blind, Randomized Trial",
    "inclusion_criteria": "* Histologically or cytologically confirmed locally advanced or metastatic solid tumors with any types. This applies to either newly diagnosed cancer or preexisting ones on treatment.\n* Patients with active cancers and currently under any line of treatment (please see notable exceptions in the exclusion criteria - patients taking checkpoint inhibitors and investigational agents will not be eligible - also exclusionary medications).\n* Patients have been taking their current anti-cancer therapy regimen for at least one month prior to enrollment (to ensure no safety or toxicity issues with study drug initiation).\n* Age â‰¥18 years.\n* ECG and lab values demonstrating adequate organ and marrow function at baseline (pre-study).\n* Negative urine drug screen for all illicit drugs and THC, CBD prior to randomization\n* Ability to understand and the willingness to sign a written informed consent document\n* Individuals able to become pregnant will agree to practice an effective form of contraception (e.g., oral birth control pills, condoms, abstinence) for the duration of enrollment (note: urine pregnancy testing will occur monthly)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of hypersensitivity to cannabis or cannabinoids\n* Current, regular use of cannabis/marijuana or THC-containing medications (dronabinol, nabilone) or cannabidiol (Epidiolex) or over-the-counter (OTC) CBD oil.\n* Concomitant use of checkpoint inhibitors (e.g., anti-PD1, PDL1, CTLA4) or other drugs for which an cannabinoid interaction may occur.\n* Current use of investigational agents, &amp;lt;3 months after the use of investigational agents\n* Cardiac conditions contraindicated for cannabis use\n* Diagnosis of HPV-related cancer, as there is some evidence that cannabis is contraindicated\n* Allergy to any constituent/ingredient contained in the edible dose\n* Psychiatric illness/social situations that would limit compliance with study requirements (e.g., bipolar disorder, psychosis, severe depression/anxiety).\n* Pregnant or breastfeeding (note: participants will be tested for pregnancy (urine sample) once per month during enrollment)\n* Current moderate/severe drug or alcohol use disorder (including cannabis use disorder), positive urine drug screen for illicit drugs or cannabis, or positive alcohol (breathalyzer) during screening\n* History of seizure disorder, epilepsy (controlled or uncontrolled)\n* Current legal obligations (parole, probation, incarceration, urine drug screen requirements as part of parole/probation/previous incarceration)\n* Currently enrolled in substance use treatment\n* Self-reported cannabis and synthetic cannabinoid use in the past 30 days (medical or non-medical use is exclusionary)\n* Self-reported illicit drug use in past 60 days (ex: methamphetamine, heroin, illicit fentanyl)\n* Self-reported daily alcohol use\n* Providing a urine sample testing positive for cannabinoids (THC, CBD) or synthetic cannabinoids (K2, Spice-like compounds)\n* Providing a sample testing positive for alcohol (breathalyzer) or non-medical use of other drugs (methamphetamine, cocaine) during screening; testing positive during enrollment will lead to discontinuation of the participant's enrollment\n* No access to internet/data or devices needed to participate in daily video calls",
    "miscellaneous_criteria": "Example"
}